Coherus divests Udenyca franchise to Intas for up to $558.4m [Yahoo! Finance]
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: Yahoo! Finance
Coherus obtained $483.4m in cash upfront on its completion, and $118.4m for the therapy's inventory. The amount is subject to post-closing adjustments. Coherus now stands to gain a further $75m in two separate milestone payments, contingent upon Intas achieving net sales targets for the therapy. Intas obtained identified assets associated with the therapy franchise, which include the pre-filled syringe, the autoinjector and the Udenyca Onbody, while also taking on certain specified liabilities. Coherus was advised by JP Morgan Securities for the financial aspects of the transaction, while Latham & Watkins provided legal advisory services to the company. Coherus BioSciences CEO and chairman Denny Lanfear stated: “With strong strategic execution, we have transformed the company while dramatically reducing our debt and leaving $250m on the post-close balance sheet. “This provides ample runway to achieve our mid-term corporate objectives, including maximising Loqtorzi revenue
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal CarcinomaGlobeNewswire
- Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic AntibodyGlobeNewswire
- Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs OfficerGlobeNewswire
- Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025GlobeNewswire
CHRS
Earnings
- 11/6/25 - Beat
CHRS
Sec Filings
- 12/9/25 - Form EFFECT
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- CHRS's page on the SEC website